Fluoropyrimidines are antimetabolite drugs widely used in the treatment of cancer including colorectal and breast cancer and cancers of the aerodigestive tract. This graphic shows candidate genes involved in the pharmacokinetics of 5-fluorouracil (5-FU), capecitabine and tegafur.
5-FU is commonly given intravenously where more than 80% of it is metabolized in the liver [Article:2656050]. Capecitabine is an oral prodrug of 5-FU which passes unaltered through the gut wall and is converted into 5'dFCR then 5'-deoxy-5-fluorouridine (5'dFUR) in the liver by carboxylesterase and cytidine deaminase respectively [Articles:9849491, 18172246]. 5'dFUR is then converted to 5-FU via thymidine phosphorylase or uridine phosphorylase [Articles:9849491, 11956089]. Tegafur is another prodrug of 5-FU that is converted by CYP2A6 to an unstable intermediate, 5-hydroxytegafur, which spontaneously breaks down to form 5-FU [Article:18172246].
There are several routes for metabolism of 5-FU, some of which lead to activation and pharmacodynamic actions of the drug. The rate-limiting step of 5-FU catabolism is dihydropyrimidine dehydrogenase (DPYD) conversion of 5-FU to dihydrofluorouracil (DHFU) [Articles:14555507, 1272473]. DHFU is then converted to fluoro-beta-ureidopropionate (FUPA) and subsequently to fluoro-beta-alanine (FBAL) by dihydropyrimidinease (DPYS) and beta-ureidopropionase (UPB1), respectively [Article:14555507]. Deficiency in enzymes in this pathway can result in severe and even fatal 5-FU toxicity. Several variants in DPYD have been associated with toxicity including (see the DPYD VIP and curated annotations for more details). Variants in DPYS have also been shown to influence 5-FU toxicity. A rare variant DPYS:833G>A (DPYS:Gly278Asp) in exon 5 was shown to be the determining variant of severe toxicity in a Dutch patient receiving 5-FU [Article:14555507]. Variants DPYS:1635delC and DPYS:Leu7Val were shown in vitro to have reduced activity [Article:18075467]. In order to modulate the activity of fluoropyrimidines, inhibitors of DPYD such as uracil and eniluracil can be coadministered. This slows the degradation of 5-FU and can improve response rate [Article:12724731].
The main mechanism of 5-FU activation is conversion to fluorodeoxyuridine monophosphate (FdUMP) which inhibits the enzyme thymidylate synthase (TYMS), an important part of the folate-homocysteine cycle and purine and pyrimidine synthesis The conversion of 5-FU to FdUMP can occur via thymidylate phosphorylase (TYMP) to fluorodeoxyuridine (FUDR) and then by the action of thymidine kinase to FdUMP or indirectly via fluorouridine monophosphate (FUMP) or fluroridine (FUR) to fluorouridine diphosphate (FUDP) and then ribonucleotide reductase action to FdUDP and FdUMP. FUDP and FdUDP can also be converted to FUTP and FdUTP and incorporated into RNA and DNA respectively which also contributes to the pharmacodynamic actions of fluoropyrimidines.
An important consideration in the use of 5-FU and related drugs is the development of drug resistance by the tumor. Some mechanisms of resistance involve expression changes in pharmacodynamic gene candidates (TYMS and P53). Drug resistance can also involve changes in drug transport. There is conflicting data about the transporters involved in the pharmacokinetics of 5-FU. SLC29A1 expression was not associated with survival in one study of pancreatic tumors [Article:18992248] but resistance/sensitivity was associated with its expression in another study of pancreatic tumor cell lines [Article:17695509]. Transport of 5-FU has been reported in an in vitro expression system of SLC22A7 [Article:15901346]. Several transporters have been implicated in 5-FU resistance including ABCG2 [Article:18820913]PMID:18837291, ABCC3, ABCC4 and ABCC5 [Article:19077464].
Thorn Caroline F, Marsh Sharon, Carrillo Michelle Whirl, McLeod Howard L, Klein Teri E, Altman Russ B. "PharmGKB summary: fluoropyrimidine pathways" Pharmacogenetics and genomics (2010).
If you would like to reproduce this PharmGKB pathway diagram:
Entities in the Pathway
Drugs/Drug Classes (3)
Relationships in the Pathway
|Arrow From||Arrow To||Controllers||PMID|
|5'-deoxy-5-fluorouridine||fluorouracil||TYMP, UPP1, UPP2||11956089, 18172246, 9849491|
|fluorouracil||fluorouridine monophosphate||PPAT, UMPS|
|fluorouridine diphosphate||FdUDP||RRM1, RRM2||12724731|
|fluorouridine diphosphate||fluorouridine triphosphate|
|fluorouridine monophosphate||fluorouridine diphosphate|
|fluroridine||fluorouridine monophosphate||UCK1, UCK2||12724731|
|fluorouracil||fluorouracil||ABCC3, ABCC4, ABCC5||19077464|
|fluorouracil||fluorouracil||ABCC4, ABCG2||18820913, 18837291, 19077464|
Download data in TSV format. Other formats are available on the Downloads/LinkOuts tab.
|Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anti-cancer drugs. 2013. Fushiya Nao, Takagi Ichiro, Nishino Hirokazu, Akizuki Setsuko, Ohnishi Akihiro.|
|Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology. 2013. Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R, Joerger M.|
|A discovery resource of rare copy number variations in individuals with autism spectrum disorder. G3 (Bethesda, Md.). 2012. Prasad Aparna, Merico Daniele, Thiruvahindrapuram Bhooma, Wei John, Lionel Anath C, Sato Daisuke, Rickaby Jessica, Lu Chao, Szatmari Peter, Roberts Wendy, Fernandez Bridget A, Marshall Christian R, Hatchwell Eli, Eis Peggy S, Scherer Stephen W.|
|Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. Asian Pacific journal of cancer prevention : APJCP. 2012. Dogan Mutlu, Karabulut Halil G, Tukun Ajlan, Demirkazik Ahmet, Utkan Gungor, Yalcin Bulent, Dincol Dilek, Akbulut Hakan, Icli Fikri.|
|Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder. Clinical genetics. 2011. Carter M T, Nikkel S M, Fernandez B A, Marshall C R, Noor A, Lionel A C, Prasad A, Pinto D, Joseph-George A M, Noakes C, Fairbrother-Davies C, Roberts W, Vincent J, Weksberg R, Scherer S W.|